2022/2 GaBI Journal Table of Contents

Contents

Editor’s Letter

What to look forward to in GaBI Journal, 2022, Issue 2

Commentary

Substitution and interchangeability: time for a conversation?

Original Research

On statistical evaluation for interchangeability of biosimilar products

A case study of AstraZeneca’s omeprazole/esomeprazole chiral switch strategy

Review Article

Manufacture and regulation of cell, tissue and gene therapy products: global perspectives, challenges and next steps

Sponsored Article

Front-loading biosimilar development with analytical characterization

Source URL: https://gabi-journal.net/2022-2-gabi-journal-table-of-contents.html